Huet, Sarah <br/><br/>
Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended.  [electronic resource] 

 -  PloS one  2014 
 - e106250 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0106250  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Female<br/>Follow-Up Studies<br/>Fusion Proteins, bcr-abl--genetics<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Glucuronidase--genetics<br/>Humans<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--diagnosis<br/>Male<br/>Middle Aged<br/>Protein Kinase Inhibitors--pharmacology<br/>RNA, Messenger--genetics<br/>Treatment Outcome